Insider Transactions Screener
Search for and identify insider purchases or sales of company shares. The screener offers additional information and analysis on the transactions and allows users to set up alerts and receive notifications when new transactions occur.
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
RF
|
John M Turner Jr
President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct | 81,356 Added 7.37% |
-
|
Apr 01
2025 |
|
RF
|
John M Turner Jr
President & CEO |
BUY
Grant, award, or other acquisition
|
Direct | 110,097 Added 10.47% |
-
|
Apr 01
2025 |
|
RF
|
John M Turner Jr
President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct | 82,975 Reduced 8.15% |
$1,789,770
$21.57 p/Share
|
Apr 01
2025 |
|
RF
|
William D. Ritter
SEVP |
SELL
Sale (or disposition) back to the issuer
|
Direct | 499 Reduced 0.79% |
$10,763
$21.57 p/Share
|
Apr 01
2025 |
|
RF
|
William D. Ritter
SEVP |
BUY
Exercise of conversion of derivative security
|
Direct | 9,298 Added 12.76% |
-
|
Apr 01
2025 |
|
RF
|
William D. Ritter
SEVP |
BUY
Grant, award, or other acquisition
|
Direct | 12,583 Added 18.83% |
-
|
Apr 01
2025 |
|
RF
|
William D. Ritter
SEVP |
SELL
Payment of exercise price or tax liability
|
Direct | 9,484 Reduced 15.04% |
$204,569
$21.57 p/Share
|
Apr 01
2025 |
|
AMAL
|
Mandy Tenner
EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 332 Reduced 1.8% |
$9,528
$28.7 p/Share
|
Apr 01
2025 |
|
DLTR
|
William W Douglas Iii
Director |
BUY
Grant, award, or other acquisition
|
Direct | 676 Added 50.0% |
$50,929
$75.34 p/Share
|
Apr 01
2025 |
|
DLTR
|
Timothy A Johnson
Director |
BUY
Grant, award, or other acquisition
|
Direct | 676 Added 50.0% |
$50,929
$75.34 p/Share
|
Apr 01
2025 |
|
BFRG,BFRGW
|
Vininder Singh
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 7,245 Reduced 0.3% |
$11,664
$1.61 p/Share
|
Apr 01
2025 |
|
NTRA
|
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct | 3,000 Reduced 2.07% |
$422,370
$140.79 p/Share
|
Apr 01
2025 |
|
NTRA
|
Gail Boxer Marcus |
BUY
Exercise of conversion of derivative security
|
Direct | 4,000 Added 22.59% |
$64,560
$16.14 p/Share
|
Apr 01
2025 |
|
NTRA
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct | 4,000 Reduced 29.19% |
$564,560
$141.14 p/Share
|
Apr 01
2025 |
|
AMAL
|
Margaret Matilda Lanning
EVP, Chief Credit Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 340 Reduced 2.59% |
$9,758
$28.7 p/Share
|
Apr 01
2025 |
|
NURO
|
Shai Gozani
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 625 Added 3.87% |
$2,756
$4.41 p/Share
|
Apr 01
2025 |
|
NURO
|
Shai Gozani
Director |
SELL
Payment of exercise price or tax liability
|
Direct | 78 Reduced 0.5% |
$343
$4.41 p/Share
|
Apr 01
2025 |
|
MGRC
|
Bradley M Shuster
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 1,000 Added 6.8% |
-
|
Apr 01
2025 |
|
NURO
|
Thomas T Higgins
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 469 Added 3.79% |
$2,068
$4.41 p/Share
|
Apr 01
2025 |
|
NURO
|
Thomas T Higgins
Director |
SELL
Payment of exercise price or tax liability
|
Direct | 76 Reduced 0.64% |
$335
$4.41 p/Share
|
Apr 01
2025 |
|
MGRC
|
William J Dawson
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 1,000 Added 14.29% |
-
|
Apr 01
2025 |
|
AMAL
|
Jason Darby
Senior Executive VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct | 569 Reduced 0.93% |
$16,330
$28.7 p/Share
|
Apr 01
2025 |
|
MGRC
|
Smita Conjeevaram
Director |
BUY
Exercise of conversion of derivative security
|
Direct | 1,000 Added 13.33% |
-
|
Apr 01
2025 |
|
IRM
|
William L Meaney
President and CEO |
SELL
Open market or private sale
|
Direct | 69,125 Reduced 100.0% |
$5,965,487
$86.3 p/Share
|
Apr 01
2025 |
|
IRM
|
William L Meaney
President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct | 69,125 Added 50.0% |
$2,529,283
$36.59 p/Share
|
Apr 01
2025 |
|
AMAL
|
Sam D. Brown
SEVP, Chief Banking Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 584 Reduced 1.35% |
$16,760
$28.7 p/Share
|
Apr 01
2025 |
|
CREX
|
David Arthur Bell
Director |
BUY
Grant, award, or other acquisition
|
Direct | 19,044 Added 27.61% |
-
|
Apr 01
2025 |
|
PLTR
|
Alexander D. Moore
Director |
SELL
Open market or private sale
|
Direct | 20,000 Reduced 1.44% |
$1,681,000
$84.05 p/Share
|
Apr 01
2025 |
|
REPL
|
Sushil Patel
Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct | 166,667 Added 31.13% |
-
|
Apr 01
2025 |
|
CREX
|
Donald A Harris
Director |
BUY
Grant, award, or other acquisition
|
Direct | 25,198 Added 12.65% |
-
|
Apr 01
2025 |
|
CREX
|
Stephen Nesbit
Director |
BUY
Grant, award, or other acquisition
|
Direct | 28,031 Added 24.24% |
-
|
Apr 01
2025 |
|
REPL
|
Andrew Schwendenman
Chief Accounting Officer |
SELL
Grant, award, or other acquisition
|
Direct | 33,333 Reduced 31.77% |
-
|
Apr 01
2025 |
|
GTX
|
Paul A Camuti
Director |
BUY
Grant, award, or other acquisition
|
Direct | 1,777 Added 7.01% |
-
|
Apr 01
2025 |
|
REPL
|
Christopher Sarchi
Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct | 45,000 Added 25.42% |
-
|
Apr 01
2025 |
|
DKNG
|
R Stanton Dodge
Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 354 Reduced 0.05% |
$11,749
$33.19 p/Share
|
Apr 01
2025 |
|
DKNG
|
R Stanton Dodge
Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 808 Added 0.12% |
-
|
Apr 01
2025 |
|
GTX
|
Joachim Drees
Director |
BUY
Grant, award, or other acquisition
|
Direct | 3,631 Added 13.71% |
-
|
Apr 01
2025 |
|
META
|
Jennifer Newstead
Chief Legal Officer |
SELL
Open market or private sale
|
Direct | 921 Reduced 2.95% |
$525,577
$570.66 p/Share
|
Apr 01
2025 |
|
REPL
|
Emily Luisa Hill
Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct | 45,000 Added 23.55% |
-
|
Apr 01
2025 |
|
VCTR
|
Amundi |
BUY
Other acquisition or disposition
|
Indirect | 3,293,471 Added 0.0% |
-
|
Apr 01
2025 |
|
GTX
|
Daniel A Ninivaggi
Director |
BUY
Grant, award, or other acquisition
|
Direct | 6,142 Added 5.0% |
-
|
Apr 01
2025 |
|
REPL
|
Konstantinos Xynos
Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct | 45,000 Added 22.51% |
-
|
Apr 01
2025 |
|
CDZI
|
Maria S. Dreyfus
Director |
BUY
Grant, award, or other acquisition
|
Direct | 6,562 Added 3.93% |
$19,161
$2.92 p/Share
|
Apr 01
2025 |
|
ANET
|
Charles H Giancarlo
Director |
SELL
Open market or private sale
|
Indirect | 8,000 Reduced 0.0% |
$620,480
$77.56 p/Share
|
Apr 01
2025 |
|
ABNB
|
Aristotle N Balogh
Chief Technology Officer |
SELL
Open market or private sale
|
Direct | 700 Reduced 0.41% |
$83,769
$119.67 p/Share
|
Apr 01
2025 |
|
BJ
|
Scott Schmadeke
EVP, Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct | 10,236 Added 24.77% |
-
|
Apr 01
2025 |
|
BJ
|
Scott Schmadeke
EVP, Chief Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 6,194 Reduced 19.58% |
$711,566
$114.88 p/Share
|
Apr 01
2025 |
|
BJ
|
William C. Werner
EVP, Strategy & Development |
BUY
Grant, award, or other acquisition
|
Direct | 20,051 Added 33.22% |
-
|
Apr 01
2025 |
|
BJ
|
William C. Werner
EVP, Strategy & Development |
SELL
Payment of exercise price or tax liability
|
Direct | 11,054 Reduced 24.19% |
$1,269,883
$114.88 p/Share
|
Apr 01
2025 |
|
ABNB
|
Brian Chesky
CEO and Chairman |
SELL
Open market or private sale
|
Direct | 38,459 Reduced 0.33% |
$4,643,155
$120.73 p/Share
|
Apr 01
2025 |